Verner-Morrison syndrome and vasoactive intestinal polypeptide (VIP).
The clinical features of the Verner-Morrison syndrome are surveyed. This rare clinical entity still needs to be more clearly defined. Especially in relation to the role of VIP and the clinical value of VIP measurements. A case with a good correlation between the activity of the disease and circulating VIP is presented.
D058186:Acute Kidney Injury / Q000097:blood; D007516:Adenoma, Islet Cell / Q000097:blood* / Q000188:drug therapy; D003681:Dehydration; D005768:Gastrointestinal Hormones / Q000097:blood*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D011863:Radioimmunoassay; D013311:Streptozocin / Q000627:therapeutic use; D013577:Syndrome; D014660:Vasoactive Intestinal Peptide / Q000097:blood*
D005768:Gastrointestinal Hormones; D014660:Vasoactive Intestinal Peptide; D013311:Streptozocin